Metabolic syndrome, insulin resistance and the risk of cardiovascular disease in HIV patients undergoing antiretroviral therapy
| Autor: | Irina Lăpădat, Adriana Hristea, Raluca Mihăilescu, Violeta Molagic, Raluca Năstase, Daniela Munteanu, Cristina Popescu, Victoria Aramă, Cătălin Tilişcan, Mirela Dinu, Sorin Ștefan Aramă, Daniela Adriana Ion, Adrian Streinu-Cercel, Mihai Lazăr, Ruxandra Moroti, Mihaela Rădulescu, Ana Maria Tudor, Anca-Ruxandra Negru |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
medicine.medical_specialty
education.field_of_study Pathology Framingham Risk Score business.industry Population Disease medicine.disease Antiretroviral therapy Insulin resistance Infectious Diseases Internal medicine Tropical medicine medicine Hiv patients Oral Presentation Metabolic syndrome education business |
| Zdroj: | BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/1471-2334-13-s1-o30 |
| Popis: | We enrolled 103 patients, including 60 males (58.3%) and 43 females (41.7%). The mean age was 32.3±13.3 years (range: 13-65 years). The median Framingham score was 1.2% (IQR=5.8%). Most patients (81.63%) had a low CVR (below 10%) and 18.37% had Framingham score values above 10%. MS and IR prevalences were 16.9% and 61.2%, respectively. CVR in the general population is primarily dependent on age. This observation was valid for our group: the median age was 24 years in people with low CVR, compared with 50 years for those with Framingham score above 10% (p=0.000). None of the antiretroviral drug classes significantly influenced CVR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|